The European Commission has taken up the European Council’s demand for deregulation of new plant breeding techniques (NBT). A new study is being conducted to form the basis for a campaign from the Commission to inform the public about the benefits of targeted mutation technologies and to break the resistance to genetically engineered crops.
Poxel SA raises €17.7m through capital increase
Latest NewsMetabolic disease specialist Poxel SA has announced a private placement of 2,358,483 new ordinary shares at €0.02 per share reserved to specified investors.
Study might prepare for rapid revision of EU GMO law
BackgroundThe European Commission has taken up the European Council’s demand for deregulation of new plant breeding techniques (NBT). A new study is being conducted to form the basis for a campaign from the Commission to inform the public about the benefits of targeted mutation technologies and to break the resistance to genetically engineered crops.
British scientists start Phase II on COVID-19 vaccine
Latest NewsResearchers at the University Oxford and AstraZeneca have started enrolment for a Phase II/III trial to test a COVID-19 vaccine in 10,000 volunteers.
Non-Executive Director for Redx Pharma
AppointmentsFrom the beginning of July, Sarah Gordon Wild will be an Independent non-Executive Director at Redx Pharma in Alderley Park, UK.
SARS-CoV2 antibody tests: not suited for individual diagnosis?
Latest NewsAn international research consortium provides data demonstrating that SARS-CoV-2 antibody tests are only useful for population-based analyses.
Vaccine to protect from any viral infection
Latest NewsTwo companies have presented a novel vaccination concept that might protect risk groups from new SARS-CoV-2 variants.
How to purify and analyze your antibodies efficiently
Sponsored PublicationsChromatography methods and practical tips to simplify and reduce the costs of your processes
Abivax bags €36m fund for COVID-19 programme
Latest NewsFrench Abivax SA has received a €36m non-dilutive funding from Bpifrance for its ABX464 Covid-19 programme.
4Teen4’s DPP3 predicts burn mortality
Latest News4TEEN4 Pharmaceuticals GmbH published data suggesting that high plasma levels of dipeptidyl peptidase 3 were indicative for upcoming multiple organ failure in burn patients.
Genentech: New Head of Research and Early Development
AppointmentsAviv Regev will follow Michael Varney as Head of Genentech Research and Early Development (gRED) at Roche subsidiary Genentech. Varney will retire from the company at the end of July.